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Abstract
Background: Chronic schizophrenic patients have been reported as having higher osteoporosis
prevalence. Survey the bone mass among schizophrenic patients and compare with that of the local
community population and reported data of the same country to figure out the distribution of bone
mass among schizophrenic patients.
Methods: 965 schizophrenic patients aged 20 years and over in Yuli Veterans Hospital and 405
members aged 20 and over of the community living in the same town as the institute received bone
mass examination by a heel qualitative ultrasound (QUS) device. Bone mass distribution was
stratified to analyzed and compared with community population.
Results: Schizophrenic patients have lower bone mass while they are young. But aging effect on
bone mass cannot be seen. Accelerated bone mass loss during menopausal transition was not
observed in the female schizophrenic patients as in the subjects of the community female
population.
Conclusion: Schizophrenic patients have lower bone mass than community population since they
are young. Further study to investigate the pathophysiological process is necessary to delay or
avoid the lower bone mass in schizophrenia patients.
Background
Osteoporosis is a bone disease that can reduce both bone
mass and bone strength. It is typically thought to be age-
related [1] and can cause serious bone fractures that can
have significant and even devastating physical, psycholog-
ical and financial consequences for patients and their fam-
ilies [2-4]. The prevalence of schizophrenia is about 1%
worldwide. Rigotti and colleagues[5] first reported
decreased bone density in patients with a confirmed men-
tal disorder as anorexia nervosa. Other researchers have
reported similar findings in anorexia [6-8]. Osteoporosis
was also reported in schizophrenia[9,10] patient and the
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prevalence of non-traumatic fractures in chronic schizo-
phrenic patients has been reported to be about 25% in a
cross-sectional survey[10]. A prevalence of osteoporosis in
chronic schizophrenic patients has been reported, but a
study of the prevalence of osteoporosis in chronic schizo-
phrenic patients on a large population has not previously
been reported. In this study, 965 chronic in-patient schiz-
ophrenic cases in Yuli Veterans hospital of Yuli town in
Taiwan were surveyed; 405 members of the community
population were also surveyed as the control group simul-
taneously. The bone mass distribution in the chronic
schizophrenic patients was evaluated and compared with
that of the community population subjects.
Methods
Study Population
The present study included 965 patients, who were older
than 20 years old, chronic schizophrenia admitted to the
Psychiatric Department of Yuli Veterans Hospital in Tai-
wan, ROC, between 2003 and 2004. All of these patients
met the DSM-IV criteria for schizophrenia as diagnosed by
psychiatrists in Yuli Veterans Hospital. Patients with
severe extra-pyramidal symptoms (EPS), poor disease
control, or severe debility that precluded cooperation with
the bone density survey were excluded from the study. For
comparison, 405 community members, who were older
than 20 years old, living in the same district as Yuli Veter-
ans Hospital, also entered the study. All residents who
lived in this district were visited at their home. Those who
were not living in Yuli Town during the survey period or
did not give consent or had medical or mental disability
that prevented them from completing the examination
were excluded. The study was approved by the medical
ethics policy of the Institutional Review Board Committee
at Yuli Veterans Hospital (serial No. 92-11-02A).
Bone Mass and Quantitative Ultrasound
A QUS-II Calcaneal Ultrasonometer (Metra Biosystems,
Mountain View, CA, USA) was used to measure bone den-
sity as broadband ultrasound attenuation (BUA) data.
Ultrasound bone densiometry is reported to correlate well
with the results of DXA and can predict osteoporosis-
related fracture[11,12] or detect bone fragility [13-15].
But there are many authors who question the precision of
peripheral bone mineral density. Some authors reported
that QUS parameters couldn't be used to predict osteope-
nia and that the sensitivities and specificities of QUS
parameters were not high enough to be used as an alterna-
tive method of dual-energy x-ray absorptiometry (DXA)
[16-19]. DXA is gold standard for measuring BMD is cur-
rently[15,20,21]. However, DXA scans are time-consum-
ing, costly and expose the patient to radiation, which
makes it a less-than-ideal method for a large population
survey. On the contrary, a calcaneal ultrasonometer is
timesaving, portable and suitable method for large sur-
veys. For this reason, we chose to use it in this study.
Osteoporosis is defined by decreased bone mineral den-
sity (BMD) to a level of or less than -2.5 SD of the mean
value of young adults. Firstly, our group assessed the pre-
cision of the quantitative ultrasound densitometry. Intra-
test precision was calculated from three repeated scans
with repositioning in 25 volunteers; the short-term coeffi-
cient of variation was 3.5% for BUA. T-scores used in our
data were calculated from measured BUA data, the appa-
ratus' specific threshold and further adjustment using data
from Chinese patients living in Taiwan as reported by N.P.
Yang[22]. Low bone mass was defined by a T-score of less
than -1.0, and severe low bone mass was defined by a T-
score of -2.5 or lower in this study. Weight and height data
were also measured and collected.
Statistical Analysis
All subjects were classified into two subject groups.
Admitted schizophrenic patients were classified as schizo-
phrenic patient group. Residents lived in the community
were classified as community population group. All the
subjects were classified into 5 age groups in decades of age
from 20 to 60 years old and 60 years above. Correlation
between measured BUA value and weight, gender, subject
groups, and age groups was tested by fractional factorial
generalized linear model. Interactions between age groups
and subject groups were also tested in the same model.
Effects of weight, gender and age groups on the differences
of means of measured BUA value was tested with general-
ized linear model in each subject group. Trends of mean
BUA values between age groups stratified by subject
groups and gender was tested by nonparametric test for
trend. Prevalence of osteoporosis data were stratified by
both gender and age groups for both groups and reported
by descriptive analysis and was compared further with the
prevalence reported in Taiwan. All statistical calculations
were conducted using the Stata 10/SE system for Mac.
Results
The demographic data and BUA value results stratified by
subject groups, age groups and gender are presented in
Table 1. There were 623 (65%) male and 342 (35%)
female patients in the schizophrenic patient group. Mean
age was 47.6 ± 15.9 (range 21–95) years in the male
patients and 46.8 ± 11.2 (range 20–78) years in the female
patients. In the community population group, there were
183 (45%) male and 222 (55%) female subjects; mean
age was 60.0 ± 18.2 (range 20–89) years in male and 54.2
± 16.0 (range 20–88) years in the female.
Mean BUA values were lower for male schizophrenic
patients as compared with male community population
group of same age groups if they were 60 years old or
younger. But mean BUA value was higher for male schiz-
ophrenic patients in the age group older than 60 years.
Mean BUA values were also lower for female schizo-
phrenic patients as compared with female communityBMC Musculoskeletal Disorders 2009, 10:1 http://www.biomedcentral.com/1471-2474/10/1
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population group of same age groups if they were younger
than 50 years old. But mean BUA values for female schiz-
ophrenic patients were higher in age groups older than 50
years. This is demonstrated in Fig. 1. A significant trend of
mean BUA value with aging was observed in males (p =
0.001) and females (p < 0.001) of community popula-
tion. It is insignificant in male and female schizophrenic
patients group.
The male schizophrenic patient group has a higher mean
weight than the male community population group
except in the age group 40–50 and the age group > 60
years old. The mean weight of the female schizophrenic
patient group is higher than the female community popu-
lation group across all age groups.
Table 2 shows the fractional factorial generalized linear
model result of subject groups, gender, weight, and age
groups on BUA. The BUA value of females is significant
lower than that of males (p < 0.001). Lean subjects have a
significantly lower BUA value (p < 0.001). The schizo-
phrenic patient group has a significantly lower BUA value
(p < 0.01). Significant effect is seen in the age groups 20–
29 (p < 0.001), 30–39 (p < 0.01) and 40–49 (p < 0.05)
years old on BUA value. Significant interaction can be
seen between subject groups and age group 50–59 and age
group > 60 years old.
Generalized linear model was used to test the effect of
gender, weight, and age on the difference of mean BUA
value and was stratified by subject groups. The result is
shown in Table 3. Males have significantly higher mean
BUA value than females in both schizophrenic patient
and community population groups (p < 0.05). Higher
BUA value can be significantly seen in heavier subjects in
both subject groups (p < 0.05 in schizophrenic patient
group, and p < 0.001 in community population group). In
the community population group, the coefficient of age is
negative and is significant (p < 0.001). But the coefficient
of age is positive and is significant also (p < 0.05) in the
schizophrenia patient group. Interaction is tested also
between age and weight and is insignificant.
Table 4 shows the comparison of prevalence of low bone
mass (t-score <-1 computed from BUA value) and severe
low bone mass (t-score % -2.5 computed from BUA value)
between schizophrenic patient group, community popu-
lation group and surveyed data in Kinmen, Taiwan[22].
The prevalence of low bone mass and severe low bone
mass is both higher in schizophrenic patients in age group
20–29 and age 30–39 years old. In age groups 40–49, 50–
59 and > 60 years old, the prevalence of low bone mass
and severe low bone mass of schizophrenic is also higher
than the community population group and the surveyed
data in Kinmen, Taiwan.
Discussion
The results of our study reveal lower BUA value in the
schizophrenic patient group while these patients are
young. The prevalence of low bone mass and severe low
bone mass showed similar changes when compared with
community populations from the same geographical area
Table 1: The Basic Characteristics of the Schizophrenic Patients compared to community population, sampled from the same 
community, Yu-Li area, Taiwan
Age Strata (y/o) Studied Subjects BUA (dB/MHz) Weight (Kgw)
Schizophrenic Community Schizophrenic Community Schizophrenic Community
No.(%) No.(%) Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.)
Male
20–29 59(9.5) 12(6.6) 77.1(15.3) 86.1(21.6) 69.3(13.9) 63.9(8.9)
30–39 184(29.5) 18(9.8) 82.3(17.0) 90.1(17.2) 71.3(19.2) 71.3(10.5)
40–49 177(28.4) 30(16.4) 83.9(18.6) 92.0(19.4) 67.2(15.3) 69.5(10.9)
50–59 77(12.4) 28(15.3) 80.3(18.2) 83.7(20.7) 67.4(13.4) 67.3(8.3)
60 or more 126(20.2) 95(51.9) 82.2(18.2) 78.0(21.1) 52.9(9.2) 66.8(10.9)
Total 623 183
Female
20–29 22(6.4) 16(7.2) 71.9(26.5) 85.3(11.1) 69.6(12.3) 53.7(7.7)
30–39 84(24.6) 33(14.9) 76.9(20.8) 85.8(11.7) 70.2(15.6) 57.3(9.9)
40–49 97(28.4) 38(17.1) 81.2(20.5) 86.3(16.9) 71.9(19.1) 59.8(10.7)
50–59 97(28.4) 45(20.3) 82.3(20.1) 72.0(16.5) 68.4(7.8) 58.0(9.2)
60 or more 42(12.3) 90(40.5) 79.0(19.9) 68.7(17.1) 65.3(6.2) 57.5(10.2)
Total 342 222
Totally 965 405BMC Musculoskeletal Disorders 2009, 10:1 http://www.biomedcentral.com/1471-2474/10/1
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and from Kinmen Island, which is in a different geograph-
ical location. The geography- related effect can be ruled
out in this study. Yuli town is in a rural area in the east part
of Taiwan. Healthier young people move to the cities for
work. For this reason, the sample size of the 20–29 and
the 30–39 year old group is small in the community pop-
ulation group. This is also the reason of higher osteoporo-
sis prevalence in the 20–29 year-old male group.
Poorer bone mass in psychiatric patients has been reported
in many literatures[9,10,23]. Since it can be seen even in the
age group 20–29 years, inadequate peak bone mass build or
accelerated bone absorption is the possible cause of low
bone mass. Reported risk factors for the increased prevalence
of osteoporosis in psychiatric patients include polydip-
sia[24], the use of neuroleptics [9,25-27] and the resulting
hyperprolactinemia[11,28-32], heavy smoking[33], poor
diet, drug and alcohol abuse[34], and lack of exercise[30].
These factors were supposed to accelerate bone absorption.
The onset of schizophrenia typically occurs during adoles-
cence and young adulthood. Therefore, the use of antipsy-
chotic medications with their attendant metabolic changes
also begins at the same stage. Lifestyle changes also begin at
about the same period. Each of these factors or a combined
effect of these factors may inhibit the build-up of peak bone
mass or accelerate bone loss, and may be the reason for low
BUA values in age groups younger than 50 years.
A rapid decrease of bone mass and an increase of oste-
oporosis during the menopausal transition are reported in
the community female population[35,36]. However, the
trend test of BUA value in female schizophrenic patients
cannot show the transition effect in our study. Hyperpro-
lactinemia caused by the medication of many kinds of
neuroleptics was suspected to suppress gonadotropins
and gonadal hormones[37,38]. Low BMD values and
hypogonadism was reported in young schizophrenic
women with hyperprolactinemia who were treated with
prolactin-raising antipsychotics[39]. Effect of decrease of
gonadotropin on bone mass during menopausal transi-
tion in female schizophrenic patients may be irrelevant
for female subjects in the community population. Further
study is necessary to explain this.
BUA vs. age with 95% confidence and fit line by subject population and sex Figure 1
BUA vs. age with 95% confidence and fit line by subject population and sex.BMC Musculoskeletal Disorders 2009, 10:1 http://www.biomedcentral.com/1471-2474/10/1
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The BUA value keeps relatively stable while aging, as
shown in trend analysis. In the generalized linear model,
BUA increased significantly with age increase. Aging is not
a risk factor of poor bone mass in schizophrenic patient
group in our study, and is a protective factor as the statis-
tical result. Aging has been reported to be a risk factor of
osteopenia in psychiatric patients treated with prolactin-
elevating antipsychotics.[40] Our study does not include
antipsychotics used to treat these patients. Classic neu-
roleptics were reported to cause hyperprolactinemia and
an increased prevalence of osteoporosis than atypical neu-
roleptics [36,37,41,42]. However, some atypical neu-
roleptic agents are reported to produce either the same or
more pronounced hyperprolactinemia[43,44]. Interac-
tion between aging and prolactin-elevating antipsychotics
may exist. Study is necessary to explore the effect of aging
on schizophrenic patients and to explore whether aging is
a protective factor.
The chronic schizophrenic patient may also have several
of the risk factors for osteoporosis-related fractures, com-
monly including unsteady gait, decreased physical activity
and the use of sedative medications and low cognitive
function. Residents of a long-term care unit are at a higher
risk of osteoporotic fractures due to one or more of fol-
lowing risk factors: advanced age, poor physical function,
low muscle strength, decreased cognition, dementia, poor
nutrition and the use of certain medications.[4] The proc-
ess of accelerated osteoporosis in schizophrenic patients
needs to be explored and may be prevented or changed to
preserve bone mass in these patients.
Conclusion
In this study, schizophrenic patients have lower BUA val-
ues since they are young when compared with the com-
munity population. Aging and menopausal transition
effect on bone mass in the general female population can-
not be seen in the schizophrenic patient group. The bone
mass distribution of schizophrenic patients is different
from that of the community population. This is a cross-
sectional study, and does not include the information of
sex hormone, bone metabolism related hormones, the
type of antipsychotic medication used and bone turnover
markers is its limitation. Use of ultrasonographic assess-
ments instead of DXA scans and the assessment of bone
mass at only one location is another limitation of this sur-
vey. Further studies are necessary to clarify the hormonal
changes, bony metabolism and effects of medication on
bone mass characteristics in schizophrenic patients. Pro-
spective study begins from the onset of schizophrenia
may be also necessary. Once the cause and effect relation-
ships are clearer, intervention may be used to either pre-
vent or delay the onset of osteoporosis in these patients.
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Table 2: Comparison of BUA in schizophrenic patient and 
community population group stratified by age group, gender by 
fractional factorial generalized linear model
(dependent variable = BUA)
Independent variables coef. std. err. p-value
Gender (female vs. male) -4.251 1.054 ***
Weight (kgw) 0.158 0.036 ***
Group#(community vs. schizophrenic) 13.069 4.096 **
Age group 20–39 -23.949 6.497 ***
Age group 30–39 -15.424 4.980 **
Age group 40–49 -10.727 4.777 *
Age group 50–59 ----- ----- n.s.
Age group ^ 60 ----- ----- n.s.
Group*Age group 20–39 ----- ----- n.s.
Group*Age group 30–39 ----- ----- n.s.
Group*Age group 40–49 ----- ----- n.s.
Group*Age group 50–59 -16.723 4.826 **
Group*Age group ^ 60 -20.967 4.563 ***
Constant 80.987 4.741 ***
n.s. : not significant
* : p < 0.05
** : p < 0.01
*** : p < 0.001
#: schizophrenic patient group and community population group
Table 3: Comparison of BUA by gender, weight, and age in schizophrenic patient and community population group with generalized 
linear model
Schizophrenic patient Community population
Independent variable β std. err. p-value β std. err. p-value
Gender (male vs female) -2.731 1.278 * -4.474 1.986 *
Weight (kgw) 0.105 0.041 * 0.445 0.086 ***
Age (years) 0.097 0.044 * -0.362 0.052 ***
Constant 73.189 4.218 *** 78.992 8.206 ***
* : p<0.05
** : p<0.01
*** : p<0.001BMC Musculoskeletal Disorders 2009, 10:1 http://www.biomedcentral.com/1471-2474/10/1
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